clinical trial · NCT07573111
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.·phase1·not yet recruiting·n = 12
Acute LeukemiaMyelodysplastic SyndromeQUAIL-100
brief summary
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
started
Jun 1, 2026
primary completion
Jun 1, 2028
completion
Mar 1, 2029
last updated
May 13, 2026
official title
An Open-label, First-in-Human, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Subjects With High-Risk Acute Leukemias and Myelodysplastic Syndrome Who Have Received a T-cell Receptor (TCR) αβ+ T Cell/CD-19+ B Cell-Depleted Hematopoietic Stem Cell Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol